| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to essential anticancer medicines for children and adolescents in Europe
|
Vassal, G.
|
|
|
32 |
4 |
p. 560-568
|
artikel
|
| 2 |
Adjuvant imatinib for GIST: duration likely matters
|
Eriksson, M.
|
|
|
32 |
4 |
p. 434-436
|
artikel
|
| 3 |
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
|
Yhim, H.-Y.
|
|
|
32 |
4 |
p. 552-559
|
artikel
|
| 4 |
Commentary: SARS-CoV-2 vaccines and cancer patients
|
Corti, C.
|
|
|
32 |
4 |
p. 569-571
|
artikel
|
| 5 |
Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”
|
Liu, S.V.
|
|
|
32 |
4 |
p. 577
|
artikel
|
| 6 |
Corrigendum to “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer”
|
Jiang, Y.
|
|
|
32 |
4 |
p. 578
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
32 |
4 |
p. iii
|
artikel
|
| 8 |
Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer
|
Bachelot, T.
|
|
|
32 |
4 |
p. 574-575
|
artikel
|
| 9 |
European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer
|
Carioli, G.
|
|
|
32 |
4 |
p. 478-487
|
artikel
|
| 10 |
Exosome-based liquid biopsies in cancer: opportunities and challenges
|
Yu, W.
|
|
|
32 |
4 |
p. 466-477
|
artikel
|
| 11 |
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
|
Casali, P.G.
|
|
|
32 |
4 |
p. 533-541
|
artikel
|
| 12 |
Have investigators forgotten how to write?
|
Tannock, I.F.
|
|
|
32 |
4 |
p. 437-438
|
artikel
|
| 13 |
Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling
|
Ococks, E.
|
|
|
32 |
4 |
p. 522-532
|
artikel
|
| 14 |
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|
Baudin, E.
|
|
|
32 |
4 |
p. 439-451
|
artikel
|
| 15 |
Multidisciplinary tumor boards as videoconferences – a new challenge in the COVID-19 era
|
Gross, M.W.
|
|
|
32 |
4 |
p. 572-573
|
artikel
|
| 16 |
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
|
Bossi, P.
|
|
|
32 |
4 |
p. 452-465
|
artikel
|
| 17 |
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
|
Wu, X.H.
|
|
|
32 |
4 |
p. 512-521
|
artikel
|
| 18 |
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study
|
Agostinetto, E.
|
|
|
32 |
4 |
p. 427-430
|
artikel
|
| 19 |
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL ☆
|
Martin, M.
|
|
|
32 |
4 |
p. 488-499
|
artikel
|
| 20 |
Postoperative ctDNA monitoring: a canary in a coalmine
|
Lumish, M.A.
|
|
|
32 |
4 |
p. 431-433
|
artikel
|
| 21 |
Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19?
|
Martin-Moreno, J.M.
|
|
|
32 |
4 |
p. 425-426
|
artikel
|
| 22 |
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆
|
Denkert, C.
|
|
|
32 |
4 |
p. 500-511
|
artikel
|
| 23 |
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆
|
Di Filippo, Y.
|
|
|
32 |
4 |
p. 542-551
|
artikel
|
| 24 |
Retraction notice to “30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)”
|
Shi, Y.
|
|
|
32 |
4 |
p. 576
|
artikel
|
| 25 |
Table of Contents
|
|
|
|
32 |
4 |
p. i-ii
|
artikel
|
Tijdschrift beschrijving